PDS Biotech to Participate at H.C. Wainwright 24th Annual Global Investment Conference
September 06 2022 - 8:00AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing a growing pipeline of targeted
cancer immunotherapies and infectious disease vaccines based on the
Company’s proprietary Versamune® and Infectimune™ T cell activating
technologies, today announced that its management will present at
the H.C. Wainwright 24th Annual Global Investment Conference being
held at the Lotte New York Palace Hotel in New York City on
September 12-14, 2022.
H.C. Wainwright Global Investment ConferenceDate: Monday,
September 12, 2022Time: On-demand presentation at 7:00 AM
EDTInvestors can register for the webcast here
Following the conference, a webcast replay of the presentation
will be available on the Investor section of the company’s website,
PDS Biotechnology.
About PDS BiotechnologyPDS Biotech is a clinical-stage
immunotherapy company developing a growing pipeline of targeted
cancer and infectious disease immunotherapies based on our
proprietary Versamune® and Infectimune™ T cell-activating
technology platforms. We believe our targeted Versamune® based
candidates have the potential to overcome the limitations of
current immunotherapy by inducing large quantities of high-quality,
highly potent polyfunctional tumor specific CD4+ helper and CD8+
killer T cells. To date, our lead Versamune® clinical candidate,
PDS0101, has demonstrated the ability to reduce tumors and
stabilize disease in combination with approved and investigational
therapeutics in patients with a broad range of HPV16-associated
cancers in multiple Phase 2 clinical trials. Our Infectimune™ based
vaccines have also demonstrated the potential to induce not only
robust and durable neutralizing antibody responses, but also
powerful T cell responses, including long-lasting memory T cell
responses in pre-clinical studies to date. To learn more, please
visit www.pdsbiotech.com or follow us on Twitter at
@PDSBiotech.
Investor Contacts:Deanne RandolphPDS BiotechPhone: +1
(908) 517-3613Email: drandolph@pdsbiotech.com
Rich CockrellCG CapitalPhone: +1 (404)
736-3838Email: pdsb@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Mar 2024 to Apr 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Apr 2023 to Apr 2024